Home
»
Pharmaceuticals
»
Pulmonary Arterial Hypertension Market Size Report, 2030

Pulmonary Arterial Hypertension Market Size, Share & Trends Report

Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class, By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), By Region, And Segment Forecasts, 2024 - 2030

Report ID: GVR-2-68038-855-8
Number of Report Pages: 150
Format: PDF

Historical Range: 2018 - 2023
Forecast Period: 2024 - 2030
Industry: Healthcare

Pulmonary Arterial Hypertension Market Summary

The global pulmonary arterial hypertension market size was estimated at USD 7,377.6 million in 2023 and is projected to reach USD 10,609.4 million by 2030, growing at a CAGR of 5.4% from 2024 to 2030. The growth of the market is mainly attributed to increasing support from government & healthcare authorities for new drug development, rising prevalence of pulmonary arterial hypertension, and favorable reimbursement policies.

Key Market Trends & Insights

In terms of region, North America was the largest revenue generating market in 2023.
Country-wise, Denmark is expected to register the highest CAGR from 2024 to 2030.
In terms of segment, prostacyclin and prostacyclin analogs accounted for a revenue of USD 3,487.0 million in 2023.
SGC Stimulators is the most lucrative drug class segment registering the fastest growth during the forecast period.

Market Size & Forecast

2023 Market Size: USD 7,377.6 Million
2030 Projected Market Size: USD 10,609.4 Million
CAGR (2024-2030): 5.4%
North America: Largest market in 2023

In addition, substantial research and development activities in field of pulmonary arterial hypertension are also projected to have positive impact on the market growth. For instance, in December 2023, a group of researchers form Cedars-Sinai revealed that unique-cell based approach is well suited for treatment of pulmonary arterial hypertension. Currently, the study in phase I of clinical trials.

North America Pulmonary Arterial Hypertension market size and growth rate, 2024 - 2030

Government support for drug development in the field of Pulmonary Arterial Hypertension (PAH) plays a crucial role in advancing research and ensuring the availability of effective treatments. PAH is a rare but severe condition characterized by high blood pressure in arteries of the lungs, leading to symptoms such as shortness of breath and fatigue. Growing prevalence of PAH is one of the factors encouraging the governments to boost drug discovery and development. According to a data published by American Journal of Managed Care in March 2021, pulmonary arterial hypertension occurs in 32.5 per million population in the U.S. and Europe.

Governments often collaborate with pharmaceutical companies, research institutions, and healthcare organizations to provide financial support, regulatory guidance, and incentives for drug development in PAH. Funding initiatives, such as grants and subsidies, enable researchers to conduct preclinical and clinical trials, facilitating the exploration of novel therapies and the enhancement of existing ones. For instance, in September 2022, Eko received funding of around USD 2.7 million from NIH for development of advanced algorithms and integrated technologies to deal with pulmonary arterial hypertension.

Regulatory agencies, like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), work closely with developers to streamline approval processes for PAH drugs. Fast-track designations, orphan drug status, and priority review pathways are some mechanisms through which governments expedite the development and approval of treatments for rare diseases like PAH. For instance, in September 2023, Merck received FDA priority review status for its Sotatercept for the treatment of pulmonary arterial hypertension in adults.

Moreover, governments may establish patient registries and databases to collect real-world data on PAH, aiding in post-marketing surveillance and long-term efficacy assessments. Collaborative efforts between public and private sectors enhance the overall landscape of PAH drug development, ensuring that innovative therapies reach patients in a timely and safe manner. Such government support is essential to addressing the unmet medical needs of individuals affected by PAH and improving their quality of life.

Market Concentration & Characteristics

Market growth stage is medium, and pace of the market growth is accelerating. The pulmonary arterial hypertension market is characterized by a high degree of innovation owing to the growing demand for advanced therapeutics and continual research & development activities. In addition, government support for drug discovery for PAH is expected to have positive impact on the market growth.

Pulmonary Arterial Hypertension Market Concentration & Characteristics

The pulmonary arterial hypertension market is also characterized by a high level funding and investments activity by the leading players, government organizations, and healthcare authorities. Such grants and funds are playing critical role in drug discovery for PAH which will eventually boost the market during the forecast period.

The market players in pulmonary arterial hypertension market are focusing on partnerships and collaborations with an aim to consolidate their position in the market. In addition, partnerships and collaborations are aiding the companies to strengthen their supply chain channels as well as technological base.

End-user concentration in context of pulmonary arterial hypertension market refers to the limited patient population, making government support crucial for drug development to address this rare and severe condition effectively.

Drug Class Insights

Prostacyclin and prostacyclin analogs led the market and accounted for 47.2% of the global revenue in 2023.Prostacyclin is a potent vasodilator and one of the most effective drugs for the treatment of PAH. It is produced from arachidonic acid through the Cyclooxygenase (COX) pathway and is released by endothelial cells in pulmonary artery. Prostacyclin binds to the prostaglandin receptors to promote relaxation of smooth muscles and vasodilation through the activation of G protein and protein kinase. According to a study published by the researchers at the American College of Cardiology in October 2023, the oral prostacyclin receptor agonist selexipag has shown promising results for treatment of PAH. Currently, the group is working on investigating the efficacy of prostacyclin for pulmonary arterial hypertension.

SGC Stimulators are estimated to register fastest CAGR during the forecast period. Soluble Guanylate Cyclase (sGC) is a core enzyme in cardiovascular system. It is also the receptor for Nitric Oxide (NO). It has emerged as a therapeutic target in cardiopulmonary diseases, such as PAH, which is associated with impaired NO synthesis. It also results in endothelial dysfunction and inadequate stimulation of the NO-sGC-cGMP pathway. This hinders vasorelaxation and smooth muscle proliferation in PAH patients.

Type Insights

Branded segment accounted for the largest share of the pulmonary arterial hypertension market in 2023. Increasing number of product approvals, strong pipeline, and heavy investments by market players are responsible for largest share of branded segment. In addition, growing number of product launches are also expected to have positive impact on the segment growth during the forecast period. For instance, in June 2022, United Therapeutics Corporation received FDA approval for its Tyvaso DPI powder for the treatment of pulmonary arterial hypertension market.

Generic type segment is estimated to register fastest CAGR during the forecast period. Certain factors such as cost, patent expiry, and availability of generics is likely to boost the growth of generic segment by 2030. In September 2022, Lupin announced launch of generic Sildenafil for the treatment of pulmonary arterial hypertension in the U.S. marketplace.

Route of Administration Insights

By Route of administration, oral segment held the largest share in pulmonary arterial hypertension market in 2023. This is attributable to growing availability of oral formulations for PAH and patient preference for oral route of administration. Letairis, Opsumit, Adcirca, and Revatio are some examples of oral PAH drugs. In addition, increasing approvals for new oral formulations are also estimated to offer favorable opportunity for segment growth during the forecast period. For instance, in November 2023, Tenax Therapeutics, Inc. received FDA approval for its TNX-103 IND application. The company is investigating oral levosimendan for the treatment of pulmonary arterial hypertension.

Global Pulmonary Arterial Hypertension market share and size, 2023

The intravenous/ subcutaneous segment is anticipated to register the fastest growth over the forecast period. Intravenous drugs offer notable benefits in the treatment of Pulmonary Arterial Hypertension (PAH). Administered directly into the bloodstream, these drugs can rapidly achieve therapeutic levels, providing prompt relief of symptoms. Intravenous delivery ensures consistent absorption and bioavailability, crucial for managing the complex pathophysiology of PAH. Moreover, this method allows for precise dosage adjustments, optimizing therapeutic outcomes.

Regional Insights

North America dominated the market and accounted for 32.1% share in 2023. Developed healthcare infrastructure in U.S. enabled access to advanced therapeutics which contributed to the growth of this region. Moreover, availability of reimbursement on PAH therapies supported the growth of North American PAH market. Growing awareness, high diagnosis rate and supportive government initiatives governed the growth of this region. Sedentary lifestyle habits such as smoking, alcohol and junk food are vital risk factors for development of PAH.

Pulmonary Arterial Hypertension Market Trends, by Region, 2024 - 2030

Asia Pacific is anticipated to witness significant growth in the pulmonary arterial hypertension market. Economic developments in countries such as India and China are expected to help market growth. High population and low per capita income led to rise in demand for affordable treatment options. MNCs are focused on investing in developing countries such as India and China. Thus, many partnerships and strategic alliances are being undertaken by organizations in this region. Further, rapid development in Asia Pacific region, high population, and improving healthcare systems are anticipated to aid in lucrative growth of the region. The Organization for Rare Diseases India (ORDI) serves as a prominent organization for all rare disease patients in India. The government has proposed substantial financial support, amounting to USD 0.18 million through the Rashtriya Arogaya Nidhi. This funding is intended for individuals needing one-time treatment under the Rare Diseases Policy 2020. Such initiative undertaken by India government are likely to play a major role in market growth.

Key Pulmonary Arterial Hypertension Company Insights

In the Pulmonary Arterial Hypertension (PAH) market, prominent players like Actelion Pharmaceuticals, a Janssen Pharmaceutical Company, engage in research, development, and commercialization of innovative PAH therapies. Their strategy includes strategic collaborations, clinical trials, and regulatory approvals to enhance their market presence. Focused on addressing unmet medical needs, these players contribute to advancements in PAH treatment, emphasizing patient outcomes and market growth.

Emerging players in the Pulmonary Arterial Hypertension (PAH) market, such as Arena Pharmaceuticals, are actively involved in developing novel therapies and expanding their portfolios. Their strategies often encompass strategic partnerships, research collaborations, and participation in clinical trials. By focusing on innovation and establishing a strong pipeline, these emerging players aim to carve a niche in the competitive PAH market, contributing to the evolution of treatment options for patients.

Key Pulmonary Arterial Hypertension Companies:

The following are the leading companies in the pulmonary arterial hypertension market. These companies collectively hold the largest market share and dictate industry trends. Financials, strategy maps & products of these pulmonary arterial hypertension companies are analyzed to map the supply network.

United Therapeutics Corporation
Bayer
Gilead Sciences, Inc.
Johnson & Johnson
Viatris Inc.
GlaxoSmithKline
Sandoz Inc.
Lupin Pharmaceuticals, Inc.
Sun Pharmaceutical Industries, Inc.
Teva Pharmaceutical Industries Ltd.

Recent Developments

In August 2023, Keros Therapeutics held a conference to present positive results for its KER-012 phase 2 clinical trial which is being conducted for investigating efficacy of the drug for treatment of pulmonary arterial hypertension.
In May 2023, Janssen Pharmaceutical Companies submitted new drug application to FDA for approval for its combination therapy of tadalafil 40mg and macitentan 10mg for the treatment of pulmonary arterial hypertension.
In April 2023, Mochida Pharmaceutical Co., Ltd. announced launch of its Treprost inhalation solution for the treatment of pulmonary arterial hypertension. The company introduced drug in Japan market.

Pulmonary Arterial Hypertension Market Report Scope

Report Attribute	Details
Market size value in 2024	USD 8.02 billion
Revenue forecast in 2030	USD 11.02 billion
Growth rate	CAGR of 5.4% from 2024 to 2030
Base year for estimation	2023
Actual years	2018 - 2023
Forecast period	2024 - 2030
Quantitative units	Revenue in USD million and CAGR from 2024 to 2030
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered	Drug Class, Type, Route Of Administration, Region
Regional scope	North America, Europe, Asia Pacific, Latin America, MEA
Country scope	U.S.; Canada; U.K.; Germany; Italy; France; Spain; Sweden; Denmark; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait
Key companies profiled	United Therapeutics Corporation; Bayer; Gilead Sciences, Inc.; Johnson & Johnson; Viatris Inc.; GlaxoSmithKline; Sandoz Inc. (Novartis); Lupin Pharmaceuticals, Inc.; Sun Pharmaceutical Industries, Inc.; Teva Pharmaceuticals Inc.
Customization scope	Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Global Pulmonary Arterial Hypertension Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global pulmonary arterial hypertension market report based on drug class, type, route of administration, and region:

Global Pulmonary Arterial Hypertension Market Report Segmentation

Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- Endothelin Receptor Antagonists (ERAs)
- PDE-5 Inhibitors
- Prostacyclin and Prostacyclin Analogs
- SGC Stimulators
Type Outlook (Revenue, USD Million, 2018 - 2030)
- Branded
- Generics
Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Oral
- Intravenous/ subcutaneous
- Inhalational
Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - U.S.
  - Canada
- Europe
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Sweden
  - Denmark
  - Norway
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - Thailand
- Latin America
  - Brazil
  - Mexico
  - Argentina
- MEA
  - South Africa
  - Saudi Arabia
  - UAE
  - Kuwait

Frequently Asked Questions About This Report

Who are the key players in the pulmonary arterial hypertension market?

b. Some key players operating in the pulmonary arterial hypertension market include United Therapeutics Corporation; Bayer; Gilead Sciences, Inc.; Johnson & Johnson; Viatris Inc.; GlaxoSmithKline; Sandoz Inc. (Novartis); Lupin Pharmaceuticals, Inc.; Sun Pharmaceutical Industries, Inc.; and Teva Pharmaceuticals Inc.

What are the factors driving the pulmonary arterial hypertension market?

b. Growing initiatives by key market players, high prevalence of PAH, adoption rate, availability of reimbursement, and entry of generics are some of the key drivers of this market.

How big is the pulmonary arterial hypertension market?

b. The global pulmonary arterial hypertension market size was estimated at USD 7.3 billion in 2022 and is expected to reach USD 7.6 billion in 2023.

What is the pulmonary arterial hypertension market growth?

b. The global pulmonary arterial hypertension market is expected to grow at a compound annual growth rate of 5.32% from 2023 to 2030 to reach USD 11.0 billion by 2030.

Which segment accounted for the largest pulmonary arterial hypertension market share?

b. North America held over 40% share of the pulmonary arterial hypertension market in 2022. The large share of the North American region is due to the developed healthcare infrastructure in the U.S. and Canada that facilitates access to advanced therapeutics. Also, increased awareness, a high diagnosis rate, and supportive government initiatives support the market growth in this region.

Request a Free Sample

Table of Contents

Chapter 1. Pulmonary Arterial Hypertension Market: Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.2.1. Information Analysis
1.2.2. Market Formulation & Data Visualization
1.2.3. Data Validation & Publishing
1.3. Research Assumptions
1.4. Information Procurement
1.4.1. Primary Research
1.5. Information or Data Analysis
1.6. Market Formulation & Validation
1.7. Market Model
1.8. Global Market: CAGR Calculation
1.9. Objective
1.9.1. Objective 1
1.9.2. Objective2
Chapter 2. Pulmonary Arterial Hypertension Market: Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Pulmonary Arterial Hypertension Market: Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Notable burden of pulmonary arterial hypertension
3.2.1.2. Supportive initiatives by public and private organizations
3.2.1.3. Supportive reimbursement policies
3.2.2. Market Restraint Analysis
3.2.2.1. Patent expiry of key drugs
3.2.2.2. Drug-related side effects
3.2.3. Market opportunity analysis
3.2.4. Market Challenge analysis
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.4. Disease Prevalence Analysis
3.5. Pipeline Analysis
3.6. Patent Expiry
3.7. Pricing Analysis
Chapter 4. Product & Service Business Analysis
4.1. Segment Dashboard
4.2. Pulmonary Arterial Hypertension Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
4.3. Endothelin Receptor Antagonists (ERAs)
4.3.1. Endothelin Receptor Antagonists (ERAs) Market, 2018 - 2030 (USD Million)
4.4. PDE-5 Inhibitors
4.4.1. PDE-5 Inhibitors Market, 2018 - 2030 (USD Million)
4.5. Prostacyclin and Prostacyclin Analogs
4.5.1. Prostacyclin and Prostacyclin Analogs Market, 2018 - 2030 (USD Million)
Chapter 5. Type Business Analysis
5.1. Segment Dashboard
5.2. Pulmonary Arterial Hypertension Market: Type Movement Analysis, 2023 & 2030 (USD Million)
5.3. Branded
5.3.1. Branded Market, 2018 - 2030 (USD Million)
5.4. Generic
5.4.1. Generic Market, 2018 - 2030 (USD Million)
Chapter 6. Route of Administration Business Analysis
6.1. Segment Dashboard
6.2. Pulmonary Arterial Hypertension Market: Route of Administration Movement Analysis, 2023 & 2030 (USD Million)
6.3. Oral
6.3.1. Oral Market, 2018 - 2030 (USD Million)
6.4. Intravenous/ Subcutaneous
6.4.1. Intravenous/ Subcutaneous Market, 2018 - 2030 (USD Million)
6.5. Inhalational
6.5.1. Inhalational Market, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
7.1. Pulmonary Arterial Hypertension Market Share By Region, 2023 & 2030
7.2. North America
7.2.1. North America Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. Key Country Dynamics
7.2.2.2. Competitive Scenario
7.2.2.3. Regulatory Framework
7.2.2.4. U.S. Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Key Country Dynamics
7.2.3.2. Competitive Scenario
7.2.3.3. Regulatory Framework
7.2.3.4. Canada Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. Key Country Dynamics
7.3.2.2. Competitive Scenario
7.3.2.3. Regulatory Framework
7.3.2.4. UK Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Key Country Dynamics
7.3.3.2. Competitive Scenario
7.3.3.3. Regulatory Framework
7.3.3.4. Germany Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. Key Country Dynamics
7.3.4.2. Competitive Scenario
7.3.4.3. Regulatory Framework
7.3.4.4. France Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Key Country Dynamics
7.3.5.2. Competitive Scenario
7.3.5.3. Regulatory Framework
7.3.5.4. Italy Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Key Country Dynamics
7.3.6.2. Competitive Scenario
7.3.6.3. Regulatory Framework
7.3.6.4. Spain Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.3.7. Sweden
7.3.7.1. Key Country Dynamics
7.3.7.2. Competitive Scenario
7.3.7.3. Regulatory Framework
7.3.7.4. Sweden Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.3.8. Norway
7.3.8.1. Key Country Dynamics
7.3.8.2. Competitive Scenario
7.3.8.3. Regulatory Framework
7.3.8.4. Norway Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.3.9. Denmark
7.3.9.1. Key Country Dynamics
7.3.9.2. Competitive Scenario
7.3.9.3. Regulatory Framework
7.3.9.4. Denmark Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.4.2. Japan
7.4.2.1. Key Country Dynamics
7.4.2.2. Competitive Scenario
7.4.2.3. Regulatory Framework
7.4.2.4. Japan Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.4.3. China
7.4.3.1. Key Country Dynamics
7.4.3.2. Competitive Scenario
7.4.3.3. Regulatory Framework
7.4.3.4. China Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. Key Country Dynamics
7.4.4.2. Competitive Scenario
7.4.4.3. Regulatory Framework
7.4.4.4. India Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.4.5. Australia
7.4.5.1. Key Country Dynamics
7.4.5.2. Competitive Scenario
7.4.5.3. Regulatory Framework
7.4.5.4. Australia Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.4.6. Thailand
7.4.6.1. Key Country Dynamics
7.4.6.2. Competitive Scenario
7.4.6.3. Regulatory Framework
7.4.6.4. Thailand Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.4.7. South Korea
7.4.7.1. Key Country Dynamics
7.4.7.2. Competitive Scenario
7.4.7.3. Regulatory Framework
7.4.7.4. South Korea Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Key Country Dynamics
7.5.2.2. Competitive Scenario
7.5.2.3. Regulatory Framework
7.5.2.4. Brazil Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.5.3. Mexico
7.5.3.1. Key Country Dynamics
7.5.3.2. Competitive Scenario
7.5.3.3. Regulatory Framework
7.5.3.4. Mexico Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.5.4. Argentina
7.5.4.1. Key Country Dynamics
7.5.4.2. Competitive Scenario
7.5.4.3. Regulatory Framework
7.5.4.4. Argentina Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.6. MEA
7.6.1. MEA Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. Key Country Dynamics
7.6.2.2. Competitive Scenario
7.6.2.3. Regulatory Framework
7.6.2.4. South Africa Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Key Country Dynamics
7.6.3.2. Competitive Scenario
7.6.3.3. Regulatory Framework
7.6.3.4. Saudi Arabia Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. Key Country Dynamics
7.6.4.2. Competitive Scenario
7.6.4.3. Regulatory Framework
7.6.4.4. UAE Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Key Country Dynamics
7.6.5.2. Competitive Scenario
7.6.5.3. Regulatory Framework
7.6.5.4. Kuwait Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization
8.2. Strategy Mapping
8.3. Company Market Share Analysis, 2023
8.4. Company Profiles/Listing
8.4.1. United Therapeutics Corporation
8.4.1.1. Overview
8.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.1.3. Product Benchmarking
8.4.1.4. Strategic Initiatives
8.4.2. Bayer AG
8.4.2.1. Overview
8.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.2.3. Product Benchmarking
8.4.2.4. Strategic Initiatives
8.4.3. Gilead Sciences, Inc.
8.4.3.1. Overview
8.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.3.3. Product Benchmarking
8.4.3.4. Strategic Initiatives
8.4.4. Johnson & Johnson Services Inc.
8.4.4.1. Overview
8.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.4.3. Product Benchmarking
8.4.4.4. Strategic Initiatives
8.4.5. Viatris Inc.
8.4.5.1. Overview
8.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.5.3. Product Benchmarking
8.4.5.4. Strategic Initiatives
8.4.6. GlaxoSmithKline
8.4.6.1. Overview
8.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.6.3. Product Benchmarking
8.4.6.4. Strategic Initiatives
8.4.7. Novartis AG
8.4.7.1. Overview
8.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.7.3. Product Benchmarking
8.4.7.4. Strategic Initiatives
8.4.8. Lupin Pharmaceuticals Inc.
8.4.8.1. Overview
8.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.8.3. Product Benchmarking
8.4.8.4. Strategic Initiatives
8.4.9. Sun Pharmaceutical Industries, Inc.
8.4.9.1. Overview
8.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.9.3. Product Benchmarking
8.4.9.4. Strategic Initiatives
8.4.10. Teva Pharmaceuticals Industries Ltd.
8.4.10.1. Overview
8.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
8.4.10.3. Product Benchmarking
8.4.10.4. Strategic Initiatives

List of Tables

Table 1. List of secondary sources
Table 2. Average selling prices for approved PAH agents in the U.S. (2023)
Table 3. Summary of pipeline analysis for Early Phase I & Phase I PAH agents
Table 4. Summary of pipeline analysis for Phase II PAH agents
Table 5. Summary of pipeline analysis for Phase III PAH agents
Table 6. Summary of pipeline analysis for Phase IV PAH agents
Table 7. Summary of pipeline analysis for Phase IV PAH agents
Table 8. Global Pulmonary Arterial Hypertension (PAH) market, by Region, 2018 - 2030 (ASP in USD)
Table 9. Global Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 10. Global Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 11. Global Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 12. Global Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (Average Selling Price in USD)
Table 13. Global Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2018 - 2030 (Million Units)
Table 14. North America Pulmonary Arterial Hypertension market, by Country, 2018 - 2030 (USD Million)
Table 15. North America Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 16. North America Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 17. North America Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (Average Selling Price in USD)
Table 18. North America Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2018 - 2030 (Million Units)
Table 19. U.S. Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 20. U.S. Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 21. U.S. Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 22. Canada Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 23. Canada Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 24. Canada Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 25. Europe Pulmonary Arterial Hypertension market, by country, 2018 - 2030 (USD Million)
Table 26. Europe Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 27. Europe Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 28. Europe Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (Average Selling Price in USD)
Table 29. Europe Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2018 - 2030 (Million Units)
Table 30. U.K. Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 31. U.K. Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 32. U.K. Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 33. Germany Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 34. Germany Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 35. Germany Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 36. France Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 37. France Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 38. France Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 39. Italy Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 40. Italy Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 41. Italy Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 42. Spain Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 43. Spain Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 44. Spain Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 45. Sweden Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 46. Sweden Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 47. Sweden Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 48. Denmark Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 49. Denmark Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 50. Denmark Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 51. Norway Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 52. Norway Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 53. Norway Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 54. Asia Pacific Pulmonary Arterial Hypertension market, by country, 2018 - 2030 (USD Million)
Table 55. Asia Pacific Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 56. Asia Pacific Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 57. Asia Pacific Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (Average Selling Price in USD)
Table 58. Asia Pacific Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2018 - 2030 (Million Units)
Table 59. China Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 60. China Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 61. China Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 62. Japan Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 63. Japan Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 64. Japan Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 65. India Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 66. India Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 67. India Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 68. Australia Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 69. Australia Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 70. Australia Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 71. South Korea Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 72. South Korea Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 73. South Korea Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 74. Thailand Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 75. Thailand Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 76. Thailand Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 77. Latin America Pulmonary Arterial Hypertension market, by country, 2018 - 2030 (USD Million)
Table 78. Latin America Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 79. Latin America Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 80. Latin America Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (Average Selling Price in USD)
Table 81. Latin America Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2018 - 2030 (Million Units)
Table 82. Brazil Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 83. Brazil Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 84. Brazil Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 85. Mexico Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 86. Mexico Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 87. Mexico Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 88. Argentina Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 89. Argentina Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 90. Argentina Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 91. MEA Pulmonary Arterial Hypertension market, by Country, 2018 - 2030 (USD Million)
Table 92. MEA Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 93. MEA Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 94. MEA Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (Average Selling Price in USD)
Table 95. MEA Pulmonary Arterial Hypertension (PAH) market, by Drug Class, 2018 - 2030 (Million Units)
Table 96. South Africa Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 97. South Africa Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 98. South Africa Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 99. Saudi Arabia Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 100. Saudi Arabia Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 101. Saudi Arabia Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 102. UAE Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 103. UAE Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 104. UAE Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)
Table 105. Kuwait Pulmonary Arterial Hypertension market, by Type, 2018 - 2030 (USD Million)
Table 106. Kuwait Pulmonary Arterial Hypertension market, by Route of Administration, 2018 - 2030 (USD Million)
Table 107. Kuwait Pulmonary Arterial Hypertension market, by Drug Class, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Pulmonary Arterial Hypertension Market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Primary research pattern
Fig. 6 Market research approaches
Fig. 7 Value-chain-based sizing & forecasting
Fig. 8 QFD modeling for Market share assessment
Fig. 9 Market formulation & validation
Fig. 10 Commodity flow analysis
Fig. 11 Market snapshot, 2023 (USD Million)
Fig. 12 Patent term expiry of the key Pulmonary Arterial Hypertension brands
Fig. 13 Ancillary Market analysis
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Consumer behavior analysis
Fig. 16 Market influencer analysis
Fig. 17 Market variables
Fig. 18 Market driver analysis
Fig. 19 Global prevalence of Pulmonary Arterial Hypertension
Fig. 20 Global geriatric population
Fig. 21 Market restraint analysis
Fig. 22 Market participant categorization
Fig. 23 Company Market position analysis: Heat map analysis
Fig. 24 Strategy mapping
Fig. 25 Market entry strategies
Fig. 26 Pulmonary Arterial Hypertension Market: Drug class dashboard
Fig. 27 Pulmonary Arterial Hypertension Market: Drug class movement analysis
Fig. 28 Prostacyclin pathway
Fig. 29 Prostacyclin and prostacyclin analogs Market, 2018 - 2030 (USD Million)
Fig. 30 Nitric oxide pathway
Fig. 31 SGC stimulators Market, 2018 - 2030 (USD Million)
Fig. 32 Endothelial pathway
Fig. 33 ERA Market, 2018 - 2030 (USD Million)
Fig. 34 PDE-5 Market, 2018 - 2030 (USD Million)
Fig. 35 Pulmonary Arterial Hypertension Market, by regions, 2018 - 2030 (USD Million)
Fig. 36 Pulmonary Arterial Hypertension Market: Type movement analysis, 2023 & 2030
Fig. 37 Pulmonary Arterial Hypertension Market Type outlook: Key takeaways
Fig. 38 Branded Market, 2018 - 2030 (USD Million)
Fig. 39 Generics Market, 2018 - 2030 (USD Million)
Fig. 40 Pulmonary Arterial Hypertension Market: Route of Administration movement analysis 2023 & 2030
Fig. 41 Pulmonary Arterial Hypertension Market Route of Administration outlook: Key takeaways
Fig. 42 Oral Market, 2018 - 2030 (USD Million)
Fig. 43 Intravenous/ subcutaneous Market, 2018 - 2030 (USD Million)
Fig. 44 Inhalational Market, 2018 - 2030 (USD Million)
Fig. 45 Intravenous/ subcutaneous Market, 2018 - 2030 (Units)
Fig. 46 Inhalational Market, 2018 - 2030 (Units)
Fig. 47 Regional Marketplace: Key takeaways
Fig. 48 Regional outlook, 2023 & 2030
Fig. 49 North America Pulmonary Arterial Hypertension Market, 2018 - 2030(USD Million)
Fig. 50 U.S. Pulmonary Arterial Hypertension Market, 2018 - 2030(USD Million)
Fig. 51 Canada Pulmonary Arterial Hypertension Market, 2018 - 2030(USD Million)
Fig. 52 Europe Pulmonary Arterial Hypertension Market, 2018 - 2030(USD Million)
Fig. 53 UK Pulmonary Arterial Hypertension Market, 2018 - 2030(USD Million)
Fig. 54 Germany Pulmonary Arterial Hypertension Market, 2018 - 2030(USD Million)
Fig. 55 France Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 56 Italy Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 57 Spain Pulmonary Arterial Hypertension Market, 2017- 2030 (USD Million)
Fig. 58 Sweden Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 59 Denmark Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 60 Norway Pulmonary Arterial Hypertension Market, 2017- 2030 (USD Million)
Fig. 61 Asia Pacific Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 62 Japan Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 63 China Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 64 India Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 65 South Korea Pulmonary Arterial Hypertension Market, 2017- 2030(USD Million)
Fig. 66 Australia Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 67 Thailand Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 68 Latin America Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 69 Brazil Pulmonary Arterial Hypertension Market, 2017 - 2086 (USD Million)
Fig. 70 Mexico Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 71 Argentina Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 72 MEA Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 73 South Africa Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 74 Saudi Arabia Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 75 UAE Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)
Fig. 76 Kuwait Pulmonary Arterial Hypertension Market, 2018 - 2030 (USD Million)

Market Segmentation

Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
- Endothelin Receptor Antagonists (ERAs)
- PDE-5 Inhibitors
- Prostacyclin and Prostacyclin Analogs
- SGC Stimulators
Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
- Branded
- Generics
Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
- Oral
- Intravenous/ subcutaneous
- Inhalational
Pulmonary Arterial Hypertension Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030) (Average Selling Price in USD ) (Volume in Million Units)
    - Endothelin Receptor Antagonists (ERAs)
    - PDE-5 Inhibitors
    - Prostacyclin and Prostacyclin Analogs
    - SGC Stimulators
  - North America Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Branded
    - Generics
  - North AmericaPulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
    - Oral
    - Intravenous/ subcutaneous
    - Inhalational
  - U.S.
    - U.S. Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - U.S. Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - U.S. Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - Canada
    - Canada Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - Canada Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - Canada Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
- Europe
  - Europe Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030) (Average Selling Price in USD ) (Volume in Million Units)
    - Endothelin Receptor Antagonists (ERAs)
    - PDE-5 Inhibitors
    - Prostacyclin and Prostacyclin Analogs
    - SGC Stimulators
  - Europe Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Branded
    - Generics
  - Europe Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
    - Oral
    - Intravenous/ subcutaneous
    - Inhalational
  - Germany
    - Germany Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - Germany Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - Germany Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - UK
    - UK Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - UK Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - UK Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - France
    - France Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - France Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - France Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - Italy
    - Italy Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - Italy Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - Italy Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - Spain
    - Spain Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - Spain Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - Spain Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - Denmark
    - Denmark Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - Denmark Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - Denmark Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - Sweden
    - Sweden Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - Sweden Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - Sweden Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - Norway
    - Norway Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - Norway Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - Norway Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
- Asia Pacific
  - Asia Pacific Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030) (Average Selling Price in USD ) (Volume in Million Units)
    - Endothelin Receptor Antagonists (ERAs)
    - PDE-5 Inhibitors
    - Prostacyclin and Prostacyclin Analogs
    - SGC Stimulators
  - Asia Pacific Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Branded
    - Generics
  - Asia Pacific Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
    - Oral
    - Intravenous/ subcutaneous
    - Inhalational
  - China
    - China Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - China Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - China Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - India
    - India Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - India Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - India Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - Japan
    - Japan Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - Japan Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - Japan Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - Australia
    - Australia Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - Australia Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - Australia Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - South Korea
    - South Korea Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - South Korea Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - South Korea Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - Thailand
    - Thailand Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - Thailand Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - Thailand Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
- Latin America
  - Latin America Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030) (Average Selling Price in USD ) (Volume in Million Units)
    - Endothelin Receptor Antagonists (ERAs)
    - PDE-5 Inhibitors
    - Prostacyclin and Prostacyclin Analogs
    - SGC Stimulators
  - Latin America Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Branded
    - Generics
  - Latin America Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
    - Oral
    - Intravenous/ subcutaneous
    - Inhalational
  - Brazil
    - Brazil Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - Brazil Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - Brazil Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - Mexico
    - Mexico Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - Mexico Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - Mexico Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - Argentina
    - Argentina Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - Argentina Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - Argentina Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
- MEA
  - MEA Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030) (Average Selling Price in USD ) (Volume in Million Units)
    - Endothelin Receptor Antagonists (ERAs)
    - PDE-5 Inhibitors
    - Prostacyclin and Prostacyclin Analogs
    - SGC Stimulators
  - MEA Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
    - Branded
    - Generics
  - MEA Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
    - Oral
    - Intravenous/ subcutaneous
    - Inhalational
  - South Africa
    - South Africa Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - South Africa Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - South Africa Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - Saudi Arabia
    - South Africa Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - South Africa Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - South Africa Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - UAE
    - UAE Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - UAE Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - UAE Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational
  - Kuwait
    - Kuwait Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
      - Endothelin Receptor Antagonists (ERAs)
      - PDE-5 Inhibitors
      - Prostacyclin and Prostacyclin Analogs
      - SGC Stimulators
    - Kuwait Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2018 - 2030)
      - Branded
      - Generics
    - Kuwait Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
      - Oral
      - Intravenous/ subcutaneous
      - Inhalational

Pulmonary Arterial Hypertension Market Dynamics

Drivers: Incidents Of Pulmonary Arterial Hypertension (PAH)

The global prevalence of PAH is very low, which is around 15 to 50 cases per million, hence, it is classified as a rare disorder. Cumulatively, the cases of PAH are in the range of 100,000 to 200,000 per year. However, in the past few years, the prevalence of this disorder has risen due to risk factors like sedentary lifestyle, HIV, smoking, alcohol/tobacco consumption, and other idiopathic conditions. PAH may occur in association with various diseases, such as lung and cardiac diseases. Frequently observed underlying causes include connective tissue disorders, congenital heart disorders, coronary artery disorder, blood clots, and high blood pressure.

Growing Geriatric Population

The presence of a large population over 60 years, which has lower immunity levels and is prone to PAH and associated diseases, is a high impact-rendering driver for the growth of the PAH market over the forecast period. Although the onset age for PAH is 45 years, it is frequently observed to occur in populations above 60 years of age. This population is expected to avail the best possible treatments, increasing the life span. The chart below forecasts the number of geriatric patients over the next 6 years who may form a routine target group contributing toward the increasing demand for PAH drugs.

Restraints: Patent Expiration Of Key Molecules

Loss of exclusivity has a direct impact on the market of branded pharmaceutical products. Also, with the Drug Price Competition and Patent Term Restoration Act, of 1984, informally known as the Hatch-Waxman Act, the development of generic drugs is encouraged, which impacts the sale of branded molecules. The license expiry of some blockbuster drugs is making way for generic drug penetration. The increased sales of generic drugs adversely affect the overall revenue generation of the market since it is 70 to 80 percent cheaper as compared to branded drugs. Cutting-edge therapies are developed for treating PAH. Therefore, the future of the pulmonary arterial hypertension market is presumed to be brighter in the years to come.

What Does This Report Include?

This section will provide insights into the contents included in this pulmonary arterial hypertension market report and help gain clarity on the structure of the report to assist readers in navigating smoothly.

Pulmonary arterial hypertension market qualitative analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Pulmonary arterial hypertension market quantitative analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

Research Methodology

A three-pronged approach was followed for deducing the pulmonary arterial hypertension market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:

Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for pulmonary arterial hypertension market to gather the most reliable and current information possible.

We buy access to paid databases such as Hoover’s and Factiva for company financials, industry information, white papers, industry journals, SME journals, and more.
We tap into Grand View’s proprietary database of data points and insights from active and archived monitoring and reporting.
We conduct primary research with industry experts through questionnaires and one-on-one phone interviews.
We pull from reliable secondary sources such as white papers and government statistics, published by organizations like WHO, NGOs, World Bank, etc., Key Opinion Leaders (KoL) publications, company filings, investor documents, and more.
We purchase and review investor analyst reports, broker reports, academic commentary, government quotes, and wealth management publications for insightful third-party perspectives.

Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of pulmonary arterial hypertension market data depending on the type of information we’re trying to uncover in our research.

Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.
Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.
Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.
Qualitative Functional Deployment (QFD) Modelling for market share assessment.

Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.

Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.
Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.
This step also entails the finalization of the report scope and data representation pattern.
Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.

Pulmonary Arterial Hypertension Market Categorization:

The pulmonary arterial hypertension market was categorized into four segments, namely drug class (Endothelin Receptor Antagonists, PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), type (Branded, Generics), route of administration (Oral, Intravenous/ subcutaneous, Inhalational), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa).

Segment Market Methodology:

The pulmonary arterial hypertension market was segmented into drug class, type, route of administration, and regions. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:

Market research approaches: Bottom-up

Demand estimation of each product across countries/regions summed up to from the total market.
Variable analysis for demand forecast.
Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.
Primary interviews for data revalidation and insight collection.

Market research approaches: Top-down

Used extensively for new product forecasting or analyzing penetration levels.
Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.
Primary interviews and vendor-based primary research for variable impact analysis.

Market research approaches: Combined

This is the most common method. We apply concepts from both the top-down and bottom-up approaches to arrive at a viable conclusion.

Regional Market Methodology:

The pulmonary arterial hypertension market was analyzed at a regional level. The globe was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into twenty-three countries, namely, the U.S.; Canada; the UK; Germany; Italy; France; Spain; Sweden; Denmark; Norway; Japan; China; India; Australia; South Korea; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait.

All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.

Pulmonary arterial hypertension market companies & financials:

The pulmonary arterial hypertension market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:

JOHNSON & JOHNSON SERVICES, INC. - Johnson & Johnson is a holding company that is involved in R&D, manufacturing, and sales of healthcare products. It operates through three reportable segments: Pharmaceuticals, Medical Devices, and Consumers. The pharmaceuticals segment focuses on infectious diseases & vaccines, immunology, neuroscience, cardiovascular, oncology, and pulmonary hypertension. The medical devices segment offers devices used in cardiovascular, orthopedic, diabetes care, surgery, and eye health fields. The consumer segment comprises oral care, baby care, beauty, women’s health, over-the-counter pharmaceuticals, and wound care. The company has an established line of pulmonary arterial hypertension treatment, owing to when it acquired the pulmonary arterial hypertension treatment line from Actelion Pharmaceuticals, Ltd. in June 2017.
GILEAD SCIENCES, INC. - Gilead Sciences, Inc. is a research-based biopharmaceutical company that caters to several life-threatening diseases such as liver diseases, HIV, cancer, inflammatory & respiratory disorders, and cardiovascular conditions. Atripla, Emtriva, Tybost, Travuda, Hepsera, Zydelig, Lexiscan, Ranexa, Tamiflu, Macugen, and Letairis are some of the key brands of the company. It has operations in North America, Europe, and Australia. The company’s cardiovascular programs and developments are managed from Fremont, California. It has manufacturing and R&D facilities across five states in the U.S.
UNITED THERAPEUTICS CORPORATION - United Therapeutics Corporation is a biotechnology company that develops, manufactures, and distributes innovative medications for chronic & life-threatening diseases. The product portfolio of the company includes pulmonary arterial hypertension and anticancer agents. It provides prostacyclin analogs and PDE-5 inhibitors, which are pulmonary arterial hypertension agents. The company is constantly innovating solutions to serve cardiovascular, pulmonary, cancer, and other orphan diseases. The company has additional facilities in North Carolina, Canada, Chertsey, Surrey, and the UK.
ACCELERON PHARMA, INC. - Acceleron Pharma, Inc. is dedicated to drug discovery, development, and marketing of therapeutics to treat rare & serious diseases. The company focuses its R&D efforts on pulmonary diseases, neuromuscular, and hematologic. The company collaborated with Celgene to develop a treatment for chronic anemia in myelodysplastic syndromes, myelofibrosis, and beta-thalassemia. The company is growing its reach in the pulmonary arterial hypertension market with its new approved drug, Sotatercept.
GLAXOSMITHKLINE PLC (GSK) - GlaxoSmithKline plc (GSK) is a healthcare company that develops, manufactures, and markets medicines, vaccines, & consumer healthcare products. In 2000, Glaxo Wellcome plc and SmithKline Beecham merged to form GSK. As of 2018, it had a presence in nearly 115 countries. The pharmaceutical segment of the company provides solutions for respiratory, oncology, immune-inflammation, and HIV. Moreover, the company has 86 manufacturing facilities across 36 countries.
PFIZER, INC. - Pfizer, Inc. is involved in the R&D and manufacturing of pharmaceutical products. It translates advanced science & technologies into efficient treatment regimens. The company focuses on major therapeutic areas such as cardiovascular diseases, vaccines, oncology, neurosciences, immunology, and rare diseases. Pfizer's R&D activities are categorized as BioTherapeutics R&D Group-involved in large-molecule research-and PharmaTherapeutics R&D Group-focused on small-molecules & related modalities discovery. The company is also engaged in investigator-initiated research and compound transfer programs for third-party agents to conduct studies.
BAYER AG - Bayer AG is a pharmaceutical and research-based company that is involved in research, manufacturing, and marketing of animal & human healthcare and medical products. The company operates through four main divisions: animal health, medical care, pharmaceuticals, and consumer care. Its consumer care division focuses on nonprescription medicines, dietary supplements, and dermatology products. The medical care division comprises blood glucose meters, diagnostic imaging agents, and mechanical systems for the treatment of constricted vessels. The company’s pharmaceuticals division focuses on prescription medicines for conditions related to the heart, infectious diseases, and others.

Value chain-based sizing & forecasting

Supply Side Estimates

Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.
Segment revenue determination via variable analysis and penetration modeling.
Competitive benchmarking to identify market leaders and their collective revenue shares.
Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.

Demand side estimates

Identifying parent markets and ancillary markets
Segment penetration analysis to obtain pertinent
revenue/volume
Heuristic forecasting with the help of subject matter experts
Forecasting via variable analysis

Pulmonary Arterial Hypertension Market Report Objectives:

Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.
Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.
Understanding market estimates and forecasts (with the base year as 2023, historic information from 2018 to 2023, and forecast from 2024 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.

Pulmonary Arterial Hypertension Market Report Assumptions:

The report provides market value for the base year 2023 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.
The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.
We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.
All market estimates and forecasts have been validated through primary interviews with the key industry participants.
Inflation has not been accounted for to estimate and forecast the market.
Numbers may not add up due to rounding off.
Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).
Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).
Latin America includes Central American countries and the South American continent
Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.

Primary Research

GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.

We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:

Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.
Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.

The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.